Observational Study Evaluating Long-term Safety of Real-world Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Damoctocog alfa pegol (Primary)
- Indications Haemophilia A; Haemorrhage
- Focus Adverse reactions
- Acronyms HA-SAFE
- Sponsors Bayer
- 02 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Status changed from not yet recruiting to recruiting.
- 10 May 2021 Planned initiation date changed from 29 Mar 2021 to 30 Jun 2021.